Randomized phase III study of selpercatinib versus cabozantinib or vandetanib in advanced, kinase inhibitornaïve, RET-mutant medullary thyroid cancer Meeting Abstract
| Authors: | Hadoux, J.; Elisei, R.; Brose, M. S.; Hoff, A.; Robinson, B.; Gao, M.; Jarzab, B.; Isaev, P.; Kopeckova, K.; Wadsley, J.; Führer, D.; Keam, B.; Sherman, E. J.; Tahara, M.; Hu, M. I.; Lin, Y.; Maeda, P.; Wirth, L. J.; Capdevila Castillon, J. |
| Abstract Title: | Randomized phase III study of selpercatinib versus cabozantinib or vandetanib in advanced, kinase inhibitornaïve, RET-mutant medullary thyroid cancer |
| Meeting Title: | ESMO Congress 2023 |
| Journal Title: | Annals of Oncology |
| Volume: | 34 |
| Issue: | Suppl. 2 |
| Meeting Dates: | 2023 Oct 20-24 |
| Meeting Location: | Madrid, Spain |
| ISSN: | 0923-7534 |
| Publisher: | Oxford University Press |
| Date Published: | 2023-10-01 |
| Start Page: | S1338 |
| Language: | English |
| ACCESSION: | WOS:001087480203588 |
| DOI: | 10.1016/j.annonc.2023.10.103 |
| PROVIDER: | wos |
| Notes: | Meeting Abstract: LBA3 -- Source: Wos |
